Supplementary Materials: Association of Genetic Variants in ANGPT/TEK and VEGF/VEGFR with Progression and Survival in Head and Neck Squamous Cell Carcinoma Treated with Radiotherapy or Radiochemotherapy

Dorota Butkiewicz, Agnieszka Gdowicz-Kłosok, Małgorzata Krześniak, Tomasz Rutkowski, Aleksandra Krzywon, Alexander Jorge Cortez, Iwona Domińczyk and Krzysztof Składowski

Table S1. SNPs selected for the study and the genotype distribution.

| Gene  | SNP   | Polymorphic Site/SNP Common Name | Location | Genotype Distribution | MAF  | HWE p-Value |
|-------|-------|----------------------------------|----------|-----------------------|------|-------------|
| VEGF  | rs2010963 | −634 G > C | 5′UTR | 201/181/40 | 0.31 | 0.94 |
|       | rs699947 | −2578 C > A | promoter | 117/204/93 | 0.47 | 0.82 |
|       | rs3025039 | 936 C > T | 3′UTR | 281/133/6 | 0.17 | 0.03 |
|       | rs699947 | −2578 C > A | promoter | 117/204/93 | 0.47 | 0.82 |
| VEGFR1| rs9582036 | −834 A > C | intron 27 | 209/169/38 | 0.29 | 0.65 |
|       | rs7996030 | c.3636−273 G > A | intron 29 | 286/114/19 | 0.18 | 0.09 |
| VEGFR2| rs2071559 | −906 T > C | promoter | 107/215/100 | 0.49 | 0.69 |
|       | rs1870377 | His472Gln, 1416 T > A | exon 11 | 223/166/28 | 0.27 | 0.70 |
| ANGPT1| rs2507800 | 1414 T > A | 3′UTR | 187/184/50 | 0.34 | 0.65 |
|       | rs1954727 | 949 G > C | 3′UTR | 144/180/97 | 0.44 | 0.006 |
| ANGPT2| rs3739391 | −79 G > A | 5′UTR | 312/101/4 | 0.13 | 0.18 |
|       | rs3020221 | Gln245Gln, 1087 C > T | exon 4 | 182/180/60 | 0.36 | 0.16 |
| TEK   | rs639225 | Ser654Ser, 1962 A > G | exon 13 | 120/196/105 | 0.48 | 0.16 |

SNP, single nucleotide polymorphism; MAF, minor allele frequency in the studied group; HWE, Hardy-Weinberg equilibrium; UTR, untranslated region; *The genotype distribution shown in order of common homozygote/heterozygote/variant homozygote.
Table S2. Stepwise multiple regression analysis for the effect of genotype combinations on OS and LRFS in the whole group, and on OS and NRFS in the combination treatment subgroup (RT + CHT).

| Variables                                      | OS          |        | Variables                                      | OS          |        |
|------------------------------------------------|-------------|--------|------------------------------------------------|-------------|--------|
| rs3739391/rs3020221/rs2010963:                  |             |        | rs3739391/rs3020221/rs2010963:                  |             |        |
| 2–3 risk genotypes                             | 1.76 (1.22–2.54) | 0.003  | 1–2 risk genotypes                              | 2.92 (1.15–7.40) | 0.024  |
| Alcohol: ever                                  | 1.46 (1.02–2.09) | 0.037  | 3–4 risk genotypes                              | 7.63 (2.77–21.06) | 8.7 × 10^5 |
| Stage N1–N3                                    | 1.66 (1.20–2.31) | 0.002  | Alcohol: ever                                   | 2.24 (1.25–4.01) | 0.007  |
| HPSCC                                          | 1.48 (1.00–2.19) | 0.049  | HPSCC                                          | 2.39 (1.46–3.93) | 5.6 × 10^4 |
| Local recurrence: yes                          | 4.56 (3.30–6.32) | <1 × 10^−6 | Local recurrence: yes                          | 5.21 (3.17–8.57) | <1 × 10^−6 |
| Regional recurrence: yes                       | 1.60 (1.08–2.36) | 0.019  | Regional recurrence: yes                        | 1.98 (1.21–3.24) | 0.007  |
| Metastasis: yes                                | 1.52 (1.02–2.26) | 0.039  | SPC: yes                                       | 1.93 (1.02–3.66) | 0.045  |
| SPC: yes                                       | 2.18 (1.46–3.26) | 0.0001 |                                                 |             |        |
| rs699947/rs1870377:                             |             |        | rs699947/rs2071559:                             |             |        |
| 2 risk genotypes                               | 1.82 (1.10–3.01) | 0.020  | 1 risk genotype                                | 4.94 (1.17–20.89) | 0.030  |
| Stage T3–T4                                    | 2.36 (1.55–3.61) | 7 × 10^−5 | 2 risk genotypes                              | 8.51 (1.92–37.69) | 0.005  |
| Non-OPSCC                                      | 2.49 (1.54–4.00) | 0.0002 |                                                 |             |        |

OS, overall survival; LRFS, local recurrence-free survival; NRFS, nodal recurrence-free survival; RT + CHT, combination therapy subgroup; HR, hazard ratio; CI, confidence interval; HPSCC, hypopharyngeal squamous cell carcinoma; SPC, second primary cancer; Non-OPSCC, non-oropharyngeal squamous cell carcinoma.